Patient-specific modeling of regional antibiotic concentration levels in airways of patients with cystic fibrosis: are we dosing high enough?

PloS One
Aukje C BosHarm A W M Tiddens

Abstract

Pseudomonas aeruginosa (Pa) infection is an important contributor to the progression of cystic fibrosis (CF) lung disease. The cornerstone treatment for Pa infection is the use of inhaled antibiotics. However, there is substantial lung disease heterogeneity within and between patients that likely impacts deposition patterns of inhaled antibiotics. Therefore, this may result in airways below the minimal inhibitory concentration of the inhaled agent. Very little is known about antibiotic concentrations in small airways, in particular the effect of structural lung abnormalities. We therefore aimed to develop a patient-specific airway model to predict concentrations of inhaled antibiotics and to study the impact of structural lung changes and breathing profile on local concentrations in airways of patients with CF. In- and expiratory CT-scans of children with CF (5-17 years) were scored (CF-CT score), segmented and reconstructed into 3D airway models. Computational fluid dynamic (CFD) simulations were performed on 40 airway models to predict local Aztreonam lysine for inhalation (AZLI) concentrations. Patient-specific lobar flow distribution and nebulization of 75 mg AZLI through a digital Pari eFlow model with mass median aerodyna...Continue Reading

Associated Clinical Trials

References

Apr 26, 2000·The European Respiratory Journal·H A TiddensJ C de Jongste
Apr 25, 2001·British Journal of Clinical Pharmacology·H Chrystyn
Apr 30, 2002·International Journal of Antimicrobial Agents·Johan W MoutonGeorge L Drusano
Aug 9, 2003·American Journal of Respiratory and Critical Care Medicine·Koichi YamazakiMasaharu Nishimura
Jan 15, 2004·American Journal of Respiratory Medicine : Drugs, Devices, and Other Interventions·Mario CazzolaSerafino A Marsico
Jan 15, 2004·American Journal of Respiratory Medicine : Drugs, Devices, and Other Interventions·Loretta M Chiu, Guy W Amsden
Mar 18, 2005·The Journal of Antimicrobial Chemotherapy·Johan W MoutonGeorge L Drusano
Jul 29, 2005·Archives of Disease in Childhood·L A WallisI Maconochie
Aug 10, 2005·The Journal of Biological Chemistry·Robert TarranRichard C Boucher
Jan 20, 2006·The New England Journal of Medicine·Scott H DonaldsonRichard C Boucher
Feb 8, 2006·Annual Review of Physiology·Robert TarranRichard C Boucher
Aug 25, 2006·Thorax·Pierre-Régis BurgelJay A Nadel
Sep 27, 2007·Journal of Aerosol Medicine : the Official Journal of the International Society for Aerosols in Medicine·M A Hasan, C F Lange
Nov 17, 2007·American Journal of Respiratory and Critical Care Medicine·Sanja StanojevicTim J Cole
Dec 22, 2007·Medical Engineering & Physics·J W De BackerW De Backer
Jul 29, 2008·American Journal of Respiratory and Critical Care Medicine·Karen S McCoyA Bruce Montgomery
Jan 19, 2010·Pediatric Pulmonology·Harm A W M TiddensPeter D Paré
Apr 30, 2010·Expert Opinion on Pharmacotherapy·J Stuart Elborn, Noreen R Henig
Oct 5, 2010·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Warren LenneyJohn M Kovarik
Nov 19, 2010·Radiology·Jan W De BackerWilfried De Backer
Jul 9, 2011·The European Respiratory Journal·E M BakkerH A W M Tiddens
Jul 14, 2011·JAMA : the Journal of the American Medical Association·Claire E WainwrightUNKNOWN ACFBAL Study Investigators
Dec 21, 2011·The European Respiratory Journal·Lieve A De BackerWilfried De Backer
Apr 3, 2012·Journal of Aerosol Medicine and Pulmonary Drug Delivery·Richard B Thompson, Warren H Finlay
Jun 13, 2012·Journal of Aerosol Medicine and Pulmonary Drug Delivery·Chantal Darquenne
Aug 4, 2012·Journal of Aerosol Medicine and Pulmonary Drug Delivery·Felix Ratjen
Oct 24, 2012·Antimicrobial Agents and Chemotherapy·Wang HengzhuangNiels Høiby
Dec 22, 2012·The European Respiratory Journal·Martine LoeveHarm A Tiddens
Jan 30, 2013·The Journal of Pediatrics·Lauren S MottUNKNOWN Australian Respiratory Early Surveillance Team for Cystic Fibrosis Study Group
Apr 19, 2013·Respiration; International Review of Thoracic Diseases·Wim VosWilfried De Backer
May 23, 2013·The New England Journal of Medicine·Stephanie D Davis, Thomas Ferkol
Sep 3, 2013·Expert Opinion on Pharmacotherapy·David HutchinsonJack Brown

❮ Previous
Next ❯

Citations

Feb 26, 2016·Journal of Aerosol Medicine and Pulmonary Drug Delivery·Janna Tenenbaum KatanJosué Sznitman
Apr 5, 2017·Journal of Clinical Pharmacy and Therapeutics·J E Moore, P Mastoridis
Jun 14, 2017·Wiley Interdisciplinary Reviews. Systems Biology and Medicine·Kelly S BurrowesHaribalan Kumar
Jan 16, 2018·Computational and Mathematical Methods in Medicine·Shouliang QiWei Qian
Nov 23, 2018·Expert Opinion on Drug Delivery·P Worth LongestMichael Hindle
Mar 19, 2019·Respirology : Official Journal of the Asian Pacific Society of Respirology·Colette Moses, Parwinder Kaur
Mar 20, 2019·Journal of Aerosol Medicine and Pulmonary Drug Delivery·Jiwoong ChoiChing-Long Lin
Aug 9, 2019·Pediatric Pulmonology·Jennifer J MeerburgHarm A W M Tiddens
Nov 13, 2019·The Journal of Pharmacy and Pharmacology·Kazunori KadotaYuichi Tozuka
Feb 20, 2020·Journal of Aerosol Medicine and Pulmonary Drug Delivery·Jennifer J MeerburgHarm A W M Tiddens
Jul 22, 2020·Drugs·Matteo BassettiMaddalena Peghin
Aug 30, 2018·BioMed Research International·Baihua ZhangJianlin Wu
Nov 6, 2018·Expert Opinion on Drug Delivery·Andrew R MartinWarren H Finlay
Nov 21, 2020·Expert Opinion on Drug Metabolism & Toxicology·Anne M Akkerman-NijlandDaniel J Touw
Jan 9, 2021·Expert Opinion on Drug Delivery·Maria Gabriella MateraMario Cazzola
Apr 8, 2021·International Journal for Numerical Methods in Biomedical Engineering·Marta TullioAndrea Aliverti
Jun 23, 2021·Respiratory Physiology & Neurobiology·Emily M DeBoerUNKNOWN AREST CF

❮ Previous
Next ❯

Methods Mentioned

BETA
genotyping

Software Mentioned

Fluent
Mimics
R
TGrid
eFlow
Matic
Pari

Related Concepts

Related Feeds

Biofilm & Infectious Disease

Biofilm formation is a key virulence factor for a wide range of microorganisms that cause chronic infections.Here is the latest research on biofilm and infectious diseases.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Biofilms

Biofilms are adherent bacterial communities embedded in a polymer matrix and can cause persistent human infections that are highly resistant to antibiotics. Discover the latest research on Biofilms here.